In the last decade there has been an exponential increase in knowledge about the genetic basis of complex human traits, including neuropsychiatric disorders. It is not clear, however, to what extent this knowledge can be used as a starting point for drug identification, one of the central hopes of the human genome project. The aim of the present study was to identify memory-modulating compounds through the use of human genetic information. We performed a multinational collaborative study, which included assessment of aversive memory—a trait central to posttraumatic stress disorder—and a gene-set analysis in healthy individuals. We identified 20 potential drug target genes in two genomewide-corrected gene sets: the neuroactive ligand-receptor interaction and the long-term depression gene set. In a subsequent double-blind, placebo-controlled study in healthy volunteers, we aimed at providing a proof of concept for the genome-guided identification of memory modulating compounds. Pharmacological intervention at the neuroactive ligand-receptor interaction gene set led to significant reduction of aversive memory. The findings demonstrate that genomewide information, along with appropriate data mining methodology, can be used as a starting point for the identification of memory-modulating compounds.

Significance

In the last decade there has been an exponential increase in knowledge about the genetic basis of complex human traits. It is not clear, however, to what extent this knowledge can be used as a starting point for drug identification, one of the central hopes of the human genome project. Here, we report that by using genomewide information related to aversive memory—a trait central to posttraumatic stress disorder—we identified several potential drug targets and compounds. In a subsequent pharmacological study with one of the identified compounds, we found a drug-induced reduction of aversive memory. These findings indicate that genomic information can be used as a starting point for the identification of memory-modulating compounds.


Conflict of interest statement: The study was done in collaboration with and was partially funded by ACImmune SA, Lausanne, Switzerland. P.P., A. Muhs, and A. Pfeifer are employees of ACImmune. A. Papassotiropoulos is scientific consultant of ACImmune. ACImmune SA and University of Basel are coapplicants. A. Papassotiropoulos and D.J.-F.D.Q. are inventors of a patent related to the use of diphenhydramine as memory modulator.

*This Direct Submission article had a prearranged editor.
as shown both in healthy subjects and in traumatized individuals (17, 23). Furthermore, we recently reported evidence suggesting a genetic link between the predisposition to build strong aversive memories and the risk for PTSD (16).

Based on these observations, we developed a process (Fig. 1) aimed at identifying gene sets related to human aversive memory, followed by a pharmacological intervention study as proof of concept for the genome guided identification of memory modulating drugs.

**Results**

**Step 1 (Gene Set Enrichment Analysis and Hypothesis-Testing Sample).** We recruited a homogenous sample of 1,802 Swiss healthy young adults who performed cognitive tasks quantifying emotional memory performance (see SI Materials and Methods for detailed sample and phenotype description). Aversive memory performance (i.e., enhanced free recall performance for previously shown pictures with negative emotional valence) (17) was the trait of interest and was analyzed as a continuous variable. SNP \( P \) values for association with aversive memory were obtained under two genetic models (i.e., additive and dominant, see SI Materials and Methods for detailed description). Only intragenic SNPs were considered. These \( P \) values served as input for subsequent identification of gene sets related to aversive memory.

We applied the improved gene set enrichment method (i GSEA4GWAS (24), which evaluates whether the distribution of genes sharing a biochemical or cellular function is different from a distribution of a ranked genomewide list of genes (see SI Materials and Methods for detailed description). Four significant [i.e., genomewide false discovery rate (FDR) corrected] gene sets related to aversive memory were detected (Table 1): the VEGF gene set, the IL1 receptor (IL1R) gene set, the long term depression gene set, and the neuroactive ligand receptor interaction gene set. By using the identical settings in this sample, we also applied a second gene set algorithm, GSA SNP (25), to assess which of these four sets are detected by another gene set method. A recent comparison of both algorithms on identical samples showed that GSA SNP tends to be more conservative than i GSEA4GWAS (26). The long term depression and the neuroactive ligand receptor interaction gene sets were detected as significant (\( P_{\text{FDRcorr}} = 0.00009 \) and \( P_{\text{FDRcorr}} = 0.006 \), respectively), whereas this was not the case for the VEGF and IL1R gene sets (\( P_{\text{FDRcorr}} = 0.5 \) and \( P_{\text{FDRcorr}} = 0.08 \), respectively).

**Step 2 (Gene Set Enrichment Analysis and Replication Sample).** In an additional population of 781 Swiss healthy young adults, who underwent the identical phenotyping and genotyping procedure as the step 1 sample, we also performed gene set enrichment analysis with the identical settings as in step 1. Gene sets analysis replicated (at the identical genome wide FDR < 0.05 level) both gene sets of the first sample, i.e., the neuroactive ligand receptor interaction set and the long term depression set (SI Materials and Methods). A total of 20 replicated genes (Table S1) within these gene sets were significantly associated with aversive memory in both the hypothesis testing (step 1; Table S1) and the replication (step 2; Table S1) samples. These genes served as input for the subsequent step 3.

**Step 3 (Drug Selection).** Here we aimed at providing a proof of concept for human genetics guided identification of memory modulating drugs. Therefore, we selected from the 20 candidate targets only gene products with already existing therapeutic compounds. Ingenuity Pathway Analysis (IPA; Ingenuity Systems) indicated the existence of therapeutic compounds for 15 of the candidate targets (Table S2). To facilitate the subsequent step 4 (pharmacological intervention study), we applied following priority criteria to these compounds with respect to their suitability in the context of a pharmacological intervention study in Switzerland: (i) existing registration as therapeutic compound by the Swiss Agency for Therapeutic Products (Swissmedic) and availability on the Swiss market; (ii) acceptable side effect profile [i.e., no major side effects such as nephrotoxicity, neuromyelotoxicity (e.g., anticancer drugs were not considered)]; and (iii) favorable application mode (e.g., oral administration was prioritized over i.v. or s.c. medication). Application of these priority criteria to the list of existing compounds (Table S2) resulted in nine compounds/compound groups (corresponding to nine genes; Table 2).

**Step 4 (Pharmacological Intervention Study).** To facilitate the selection of one drug for a proof of concept study, we studied which of the nine high priority genes are also linked to highly aversive (traumatic) memory in a population of 349 severely traumatized genocide survivors (16) (SI Materials and Methods). After correction for multiple comparisons, one gene (HRH1) was found to be associated with traumatic memory (Table S3). Therefore, compounds targeting the histamine 1 receptor (encoded by HRH1) were given highest priority for this proof of concept intervention study. Two drug groups are known to interact with the histamine 1 receptor: antipsychotics (e.g., olanzapine) and antihistamines (e.g., diphenhydramine). Antipsychotics were considered to have an unfavorable side effect profile relatively to antihistamines. Therefore, an antihistamine known to cross the blood brain barrier (diphenhydramine) was selected for the subsequent intervention study. To our knowledge, the effect of diphenhydramine on emotional memory has not been studied to date.

The study with the HRH1 antagonist diphenhydramine was carried out using a double blind, placebo controlled, cross over design in 40 healthy, young (23.0 ± 0.8 yr; 21 males) volunteers of European ancestry. Subjects received a single oral administration...
Table 1. Gene sets related to aversive memory (testing sample)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>VEGF pathway</td>
<td>biocarta.com/pathfiles/hsa05943/VEGFPATHWAY.asp</td>
<td>&lt;0.001</td>
<td>0.011</td>
<td>10</td>
<td>21</td>
<td>28</td>
</tr>
<tr>
<td>IL1R pathway</td>
<td>biocarta.com/pathfiles/hsa04010/IL1RPATHWAY.asp</td>
<td>&lt;0.001</td>
<td>0.013</td>
<td>13</td>
<td>24</td>
<td>33</td>
</tr>
<tr>
<td>HSA04730 LONG TERM DEPRESSION</td>
<td>genome.jp/dbget-bin/www.bget?pathway=hsa04730</td>
<td>&lt;0.001</td>
<td>0.019</td>
<td>33</td>
<td>67</td>
<td>76</td>
</tr>
<tr>
<td>HSA04080 NEUROACTIVE LIGAND RECEPTOR INTERACTION</td>
<td>genome.jp/dbget-bin/www.bget?pathway=hsa04080</td>
<td>&lt;0.001</td>
<td>0.036</td>
<td>69</td>
<td>175</td>
<td>254</td>
</tr>
</tbody>
</table>

All gene set genes, all genes of a given gene set, i.e., mapped and unmapped genes; mapped gene set genes, gene set genes containing at least one intragenic SNP and therefore included in the iGSEA analysis; significant gene set genes, genes mapped with at least one of the top 5% of all nominally significant SNPs (Materials and Methods).

of diphenhydramine 50 mg or placebo in a cross over design with 7 ± 3 d between visits (for flow diagram, see Fig. S1). Three hours after administration of the study medication, subjects underwent comprehensive emotional and cognitive testing (SI Materials and Methods).

As expected, diphenhydramine significantly increased sleepiness (as measured with a visual analog scale during the test phase, P < 0.001; Table S4). Therefore, drug induced sleepiness, which reflects the activity of centrally acting antihistamines (27), was used as a between subjects factor in the statistical analysis of drug effects on memory (SI Materials and Methods).

The primary outcome variable (i.e., aversive memory) was normally distributed (Shapiro Wilk test: P > 0.5). We observed a significant effect of diphenhydramine on free recall performance for aversive pictures as early as 5 min after picture presentation (P < 0.05; Table 3) and also after a longer delay (90 min after picture presentation; P = 0.008; Table 3). The effect size of diphenhydramine on free recall of aversive pictures (90 min delay) was medium (Cohen’s d = 0.42). The effect of diphenhydramine on 90 min delayed free recall of aversive pictures was also significant after correcting for sex (P = 0.006), age (P = 0.009), treatment order (P = 0.012), and body weight (P = 0.009). There was no main effect of treatment order (P = 0.647) on recall performance and no significant order × treatment interaction (P = 0.266).

The statistical model including treatment (placebo, diphenhydramine) and all three valence groups (positive, neutral, aversive) as independent variables in this repeated measures ANOVA and sleepiness as between subject factor revealed a significant main effect of valence (P < 0.001), a significant main effect of treatment (P = 0.023), and a significant treatment × valence × sleepiness interaction (P = 0.02). Post hoc analyses revealed that diphenhydramine reduced recall of aversive information significantly (P < 0.001; Fig. 2 and Table S5) in subjects who reported diphenhydramine induced sleepiness, but not significantly (P > 0.9) in subjects who did not report diphenhydramine induced sleepiness (SI Materials and Methods).

There were no significant drug effects on the recall of positive or neutral pictures in the entire sample (Table 3) and also no significant drug effects on the recall of positive or neutral pictures after stratification for sleepiness (high sleepiness/positive pictures: P = 0.328; no sleepiness/positive pictures: P = 0.411; high sleepiness/negative pictures: P = 0.384; no sleepiness/negative pictures: P = 0.181). These findings show that diphenhydramine did not affect memory for neutral or positive pictures despite its sedative effect. Thus, diphenhydramine induced sleepiness did not interfere with general mnemonic processes. This finding is in line with previous studies, which consistently report that diphenhydramine does not affect nonemotional, episodic memory (28–31).

Furthermore, we did not observe a significant (P = 0.26) correlation between sleepiness and aversive memory in the placebo condition, although large interindividual variability in sleepiness was observed in that group [3.06 ± 2.12 (mean ± SD); range, 0–8, on a visual analog scale from 0 to 10]. This finding...
Table 3. Drug effects on free recall of pictures

<table>
<thead>
<tr>
<th>Memory type</th>
<th>Diphenhydramine mean (SE)</th>
<th>Placebo mean (SE)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short delay (5 min) free recall of pictures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive pictures</td>
<td>13.53 (0.49)</td>
<td>14.32 (0.58)</td>
<td>0.110</td>
</tr>
<tr>
<td>Neutral pictures</td>
<td>9.03 (0.55)</td>
<td>10.36 (0.53)</td>
<td>0.032</td>
</tr>
<tr>
<td>Aversive pictures</td>
<td>13.15 (0.55)</td>
<td>14.41 (0.44)</td>
<td>0.014*</td>
</tr>
<tr>
<td>Long delay (90 min) free recall of pictures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive pictures</td>
<td>13.92 (0.55)</td>
<td>14.56 (0.54)</td>
<td>0.197</td>
</tr>
<tr>
<td>Neutral pictures</td>
<td>9.40 (0.62)</td>
<td>10.36 (0.63)</td>
<td>0.114</td>
</tr>
<tr>
<td>Aversive pictures</td>
<td>13.68 (0.60)</td>
<td>14.92 (0.47)</td>
<td>0.008*</td>
</tr>
</tbody>
</table>

Cross over study with 40 healthy subjects. P indicates nominal P values.
*Significance after Bonferroni correction for the three valence groups.

Discussion

The present study demonstrates the potential of the use of genomic information for the identification of drugs influencing emotionally aversive memory. Specifically, genomewide gene set analyses pointed to HRH1 (encoding histamine receptor H1) as one of many possible drug targets. A subsequent double blind, placebo controlled intervention study in healthy volunteers revealed that single dose administration of the antihistamine diphenhydramine led to significant reduction of aversive memory recall but not of general mnemonic functions. Although SNP based association studies represent a valuable tool for the identification of druggable molecules, it is important to note that genetic signals arising from marker SNPs generally do not allow inferences about functional consequences at the mRNA or protein expression level, nor do they predict the direction of drug effects. Consequently, subsequent molecular and pharmacological studies in animals or humans are needed to corroborate the genetic association results and to define the direction of effect of a drug identified through SNP based association.

It is important to stress that in the present study the priority criteria for the compound tested in the intervention study were weighted toward feasibility. For example, only compounds registered in Switzerland and available in the Swiss market were considered in this study. Consequently, a number of interesting compounds (Table S2) are also potentially efficacious and may be considered as candidates for following clinical trials. For example, the drug discovery approach described herein also identified morphine as a drug with potential aversive memory modulating properties (Table S2). Interestingly, the use of morphine after combat injury was recently associated with reduced risk for the development of PTSD (35).

The present study also demonstrates the feasibility and importance of gene set based analytical methods, which identify biologically meaningful groups of genes associated with a certain trait, rather than focusing on single GWAS gene loci (10). Two replicated gene sets related to aversive memory were identified in the present study: the long term depression gene set and the neuroactive ligand receptor interaction gene set. Both sets include genes intimately involved in learning and memory processes with well established roles in crucial neuronal traits such as plasticity and synaptic function.

To test whether the identification of these brain related gene sets is a function of the core phenotype under study, i.e., aversive memory, we conducted an additional study on a brain unrelated trait: rheumatoid arthritis (RA: Tables S7, S8, and S9). Specifically, we applied the identical search strategy (i.e., gene set enrichment analysis and Ingenuity based compound search) to

![Fig. 2. Diphenhydramine induced reduction of aversive memory in the high sleepiness group (n = 20). A single administration of diphenhydramine (50 mg) compared with placebo significantly reduced delayed recall of aversive, but not of positive or neutral, pictures (Table S5). Diphenhydramine did not affect valence or arousal ratings (P > 0.2) of the presented pictures. Error bars represent SEM.](image-url)
a large dataset \( (n = 25,500) \) of patients with RA and controls (36). SNP to gene assignment and correction for multiple comparisons were done as reported for the aversive memory study. Gene set enrichment analysis retrieved six genomewide corrected gene sets related to RA, including sets relevant to inflammation, antigen presentation, and cell adhesion (Tables S7 and S8). Interestingly, most of the existing compounds identified are characterized by immunomodulatory properties (Table S9), and for several of the retrieved drugs, the primary indication is RA (e.g., Abatacept, Belatacept, Anakinra, Tocilizumab, Adalimumab, Iliximab, and Etanercept; Table S9). This result demonstrates the face validity of the gene set approach and suggests that the identification of brain related groups of genes was a function of the core phenotype under study.

Although the present results underscore the importance and potential of genetic studies of human complex traits for the identification of therapeutic compounds, we would like to point out that the approach described herein is one of many possible approximations. Despite current lack of evidence, we hope that future developments related to both the understanding of the human genome and to the progress in biostatistical methodology will improve this concept. First, genetics guided drug discovery might be improved by the rapid development of affordable whole genome sequencing technologies. Indeed, the vast majority of genetic association studies to date are based on the concept of proxy SNPs. As a consequence, many genes remain uncovered by common SNPs and are thereby a priori excluded from further analysis. SNP to gene assignment and correction for multiple comparisons were done as reported for the aversive memory study (36). SNP to gene assignment and correction for multiple comparisons were done as reported for the aversive memory study (36).

Materials and Methods

Step 1 involved a homogenous sample of 1,802 (1,211 females and 591 males) Swiss healthy young (22.4 ± 0.1 y; mean ± SE) adults who performed a memory task consisting of freely recalling previously presented aversive, positive, and neutral pictures. In this sample, we applied the improved gene set enrichment method (24) and a second gene set algorithm GSA SNP (25). In step 2, we performed a replication study in 781 (484 females and 297 males) Swiss healthy young (22.4 ± 0.1 y) adults. In step 3, we used the Ingenuity Pathway Analysis (IPA; Ingenuity Systems) to identify therapeutic compounds for the identified candidate genes. In step 4, to facilitate the selection of one drug for a proof of concept pharmacological study, we studied which of the nine high priority genes are also linked to highly aversive (traumatic) memory in a population of 349 severely traumatized genocide survivors. Finally, we performed a double blind, placebo controlled, cross over pharmacological study in 40 healthy, young (23.0 ± 0.8 y; 21 males) volunteers. Subjects received a single oral administration of diphenhydramine 50 mg or placebo in a cross over design with 7 ± 3 d between visits. For a detailed description of the study populations, designs, and procedures of steps 1–4, see SI Material and Methods.

ACKNOWLEDGMENTS. This work was funded by Swiss National Science Foundation Sinergia Grants CRSIK0 122691 and CRSII3 130080 (to D.J. F.d.Q. and A. Papassotropoulos) and by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft; to I. T.K. and T.E.).


